AFX2

Data speaks louder than words

Committed to clinical outcomes

that meet your demands.

Five-Year Results of the LEOPARD RCT now published in JVS.

The first-ever head-to-head comparison of EVAR

endograft systems in a real-world population.

AFX2 Endovascular AAA System

demonstrated positive 5-year results

and similar outcomes to commercially available endografts in the LEOPARD randomized controlled trial.

The LEOPARD trial is the first RCT comparing an anatomically fixated endograft (AFX/AFX2) to proximal fixation endografts; and demonstrated¹ the following:

0 %

Freedom from rupture

0 %

Freedom
from ARM*

0 %

AFX/AFX2 type III endoleak rate at 5 years

*ARM: Aneurysm-Related Mortality

Freedom-from event estimates were comparable to contemporary proximal fixation endografts.

“Importantly, the comparable performance results from the LEOPARD study between AFX/AFX2 and other endografts align with a recent publication¹ that was authored on behalf of the Society for Vascular Surgery’s Patient Safety Organization and used linked registry claims data”

Matt Thompson, MD

Review the publication summary:^{^}

^Publication Summary from BMJ: Use of linked registry claims data for long term surveillance of devices after endovascular abdominal aortic aneurysm repair: observational surveillance study²

The published study set out to evaluate long term outcomes (reintervention and late rupture of abdominal aortic aneurysm) of aortic endografts in real world practice using linked registry claims data.

Overcome common challenges seen in specific anatomies.

Bifurcated unibody design preserves the native bifurcation and separates graft fixation from the sealing zone

Unibody design mimics the natural aorta, no competing limbs, and enables “up and over” procedures for future endovascular interventions

AFX2 System’s ActiveSeal^® technology conforms to the aortic wall

Establishes seal and adjusts to changes that may occur to the aortic neck, allowing the graft material to billow and adapt to the patient’s anatomy

Explore the AFX2 System key design features here:

Less Time, Intuitive Design, Greater Efficiency

Shorter times for overall procedure, fluoroscopy and anesthesia as a well as less contrast used on average compared to proximal fixation.¹

Shorter procedure times

Reduced fluoroscopy time

Less contrast volume

Explore how you can save time and resources

with the AFX2 System

Contact Us:

First Name

Last Name

State

City

Postal Code

Country

Speciality

Message

If you are human, leave this field blank.

I want to explore further:

AFX2 Downloads:

Other Links:

Related Studies

News

For information on Endologix’s privacy practices, see our Privacy Statement

REFERENCES

Kwolek CJ, Ouriel K, Stucky FS, et al. Five-year results of the Leopard Trial of commercially available endografts. Journal of Vascular Surgery. Published online 2023. doi:10.1016/j.jvs.2023.04.011
Goodney, P, Mao J, Columb J, Suckow B, Schermerhorn M, Malas M, et al. Use of linked registry claims data for long term surveillance of devices after endovascular abdominal aortic aneurysm repair: observational surveillance study. BMJ 2022;379:e071452.

Legal Information:

AFX2 Endovascular AAA System

INDICATIONS FOR USE (US):
The Endologix^® AFX^®2 Endovascular AAA System is indicated for endovascular treatment in patients with AAA using a surgical vascular access technique or a bilateral percutaneous technique. The devices are indicated for patients with suitable aneurysm morphology for endovascular repair, including: Adequate iliac/femoral access compatible with the required delivery systems (diameter ≥ 6.5 mm); Non-aneurysmal aortic neck between the renal arteries and the aneurysm: with a length of ≥ 15 mm; with a diameter of ≥ 18 mm and ≤ 32 mm; with a neck angle of ≤ 60° to the body of the aneurysm. Aortic length ≥ 1.0 cm longer than the body portion of the chosen bifurcated model. Common iliac artery distal fixation site: with a distal fixation length of ≥ 15 mm; with ability to preserve at least one hypogastric artery; with a diameter of ≥ 10 mm and ≤ 23 mm; with an iliac angle of ≤ 90° to the aortic bifurcation. Extension stent grafts must have the ability to overlap the bifurcated stent graft by at least 30 to 40 mm proximally and at least 15 to 20 mm distally.

INDICATIONS FOR USE (EU):
The Endologix^® AFX^®2 Endovascular AAA System is indicated for endovascular treatment in patients with AAA using a surgical vascular access technique. The devices are indicated for patients with suitable aneurysm morphology for endovascular repair, including: Adequate iliac/femoral access compatible with the required delivery systems (diameter ≥ 6.5 mm); Non-aneurysmal aortic neck between the renal arteries and the aneurysm: with a length of ≥ 15 mm; with a diameter of ≥ 18 mm and ≤ 32 mm; with a neck angle of ≤ 60° to the body of the aneurysm. Aortic length ≥ 1.0 cm longer than the body portion of the chosen bifurcated model. Common iliac artery distal fixation site: with a distal fixation length of ≥ 15 mm; with ability to preserve at least one hypogastric artery; with a diameter of ≥ 10 mm and ≤ 23 mm; with an iliac angle of ≤ 90° to the aortic bifurcation. Extension stent grafts must have the ability to overlap the bifurcated stent graft by at least 30 to 40 mm proximally and at least 15 to 20 mm distally.

CONTRAINDICATIONS:
The Endologix^® AFX^®2 Endovascular AAA System is contraindicated for use in patients who have a condition that threatens to infect the graft and in patients with sensitivities or allergies to the device materials. Refer to the Instructions for Use for more information concerning Indications, Contraindications, Warnings and Precautions, and Adverse Events.

CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician. Rx only.

Note: Endologix products and associated components are not available in all countries or regions. Please consult with your Endologix representative for details regarding product availability.

CE marked. Please refer to current product instructions for use.

Endologix®, AFX®2, ALTO®, DuraPly®, VELA®, and ActiveSeal® are registered trademarks of Endologix LLC in the United States and certain foreign countries. All other trademarks are the property of their respective owners.